{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T17:04:55Z","timestamp":1794330295334,"version":"4.9.0"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2023,12,27]],"date-time":"2023-12-27T00:00:00Z","timestamp":1703635200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,12,27]],"date-time":"2023-12-27T00:00:00Z","timestamp":1703635200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100012030","name":"Yakult Honsha","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100012030","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Hematol"],"published-print":{"date-parts":[[2024,2]]},"DOI":"10.1007\/s12185-023-03689-6","type":"journal-article","created":{"date-parts":[[2023,12,27]],"date-time":"2023-12-27T09:02:36Z","timestamp":1703667756000},"page":"156-163","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Japanese phase Ib study of the oral PI3K-\u03b4 and -\u03b3 inhibitor duvelisib in patients with relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma"],"prefix":"10.1007","volume":"119","author":[{"given":"Shinichi","family":"Makita","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuichi","family":"Ota","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuko","family":"Mishima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kensuke","family":"Usuki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daisuke","family":"Ennishi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masamitsu","family":"Yanada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noriko","family":"Fukuhara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryusuke","family":"Yamamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atsushi","family":"Takamine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Go","family":"Nohara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koji","family":"Izutsu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,12,27]]},"reference":[{"key":"3689_CR1","doi-asserted-by":"publisher","first-page":"536","DOI":"10.1111\/bjh.12659","volume":"164","author":"D Chihara","year":"2014","unstructured":"Chihara D, Ito H, Matsuda T, Shibata A, Katsumi A, Nakamura S, et al. Differences in incidence and trends of haematological malignancies in Japan and the United States. Br J Haematol. 2014;164:536\u201345.","journal-title":"Br J Haematol"},{"key":"3689_CR2","doi-asserted-by":"publisher","first-page":"5843","DOI":"10.1002\/cam4.1805","volume":"7","author":"R Muto","year":"2018","unstructured":"Muto R, Miyoshi H, Sato K, Furuta T, Muta H, Kawamoto K, et al. Epidemiology and secular trends of malignant lymphoma in Japan: Analysis of 9426 cases according to the World Health Organization classification. Cancer Med. 2018;7:5843\u201358.","journal-title":"Cancer Med"},{"key":"3689_CR3","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1056\/NEJMoa1215637","volume":"369","author":"JC Byrd","year":"2013","unstructured":"Byrd JC, Furman RR, Coutre SE, Flinn IW, Burger JA, Blum KA, et al. Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia. N Engl J Med. 2013;369:32\u201342.","journal-title":"N Engl J Med"},{"key":"3689_CR4","doi-asserted-by":"publisher","first-page":"2425","DOI":"10.1056\/NEJMoa1509388","volume":"373","author":"JA Burger","year":"2015","unstructured":"Burger JA, Tedeschi A, Barr PM, Robak T, Owen C, Ghia P, et al. Ibrutinib as initial therapy for patients with chronic lymphocytic leukemia. N Engl J Med. 2015;373:2425\u201337.","journal-title":"N Engl J Med"},{"key":"3689_CR5","doi-asserted-by":"publisher","first-page":"2849","DOI":"10.1200\/JCO.19.03355","volume":"38","author":"P Ghia","year":"2020","unstructured":"Ghia P, Pluta A, Wach M, Lysak D, Kozak T, Simkovic M, et al. ASCEND: Phase III, Randomized Trial of Acalabrutinib Versus Idelalisib Plus Rituximab or Bendamustine Plus Rituximab in Relapsed or Refractory Chronic Lymphocytic Leukemia. J Clin Oncol. 2020;38:2849\u201361.","journal-title":"J Clin Oncol"},{"key":"3689_CR6","doi-asserted-by":"publisher","first-page":"1278","DOI":"10.1016\/S0140-6736(20)30262-2","volume":"395","author":"JP Sharman","year":"2020","unstructured":"Sharman JP, Egyed M, Jurczak W, Skarbnik A, Pagel JM, Flinn IW, et al. Acalabrutinib with or without obinutuzumab versus chlorambucil and obinutuzumab for treatment-naive chronic lymphocytic leukaemia (ELEVATE TN): a randomised, controlled, phase 3 trial. Lancet. 2020;395:1278\u201391.","journal-title":"Lancet"},{"key":"3689_CR7","doi-asserted-by":"publisher","first-page":"1973","DOI":"10.1200\/JCO.2017.76.6840","volume":"36","author":"S Stilgenbauer","year":"2018","unstructured":"Stilgenbauer S, Eichhorst B, Schetelig J, Hillmen P, Seymour JF, Coutre S, et al. Venetoclax for patients with chronic lymphocytic leukemia with 17p deletion: results from the full population of a phase II pivotal trial. J Clin Oncol. 2018;36:1973\u201380.","journal-title":"J Clin Oncol"},{"key":"3689_CR8","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1200\/JCO.18.01580","volume":"37","author":"AP Kater","year":"2019","unstructured":"Kater AP, Seymour JF, Hillmen P, Eichhorst B, Langerak AW, Owen C, et al. Fixed duration of venetoclax-rituximab in relapsed\/refractory chronic lymphocytic leukemia eradicates minimal residual disease and prolongs survival: post-treatment follow-up of the MURANO phase III study. J Clin Oncol. 2019;37:269\u201377.","journal-title":"J Clin Oncol"},{"key":"3689_CR9","doi-asserted-by":"publisher","first-page":"2225","DOI":"10.1056\/NEJMoa1815281","volume":"380","author":"K Fischer","year":"2019","unstructured":"Fischer K, Al-Sawaf O, Bahlo J, Fink AM, Tandon M, Dixon M, et al. Venetoclax and Obinutuzumab in Patients with CLL and Coexisting Conditions. N Engl J Med. 2019;380:2225\u201336.","journal-title":"N Engl J Med"},{"key":"3689_CR10","doi-asserted-by":"publisher","first-page":"997","DOI":"10.1056\/NEJMoa1315226","volume":"370","author":"RR Furman","year":"2014","unstructured":"Furman RR, Sharman JP, Coutre SE, Cheson BD, Pagel JM, Hillmen P, et al. Idelalisib and rituximab in relapsed chronic lymphocytic leukemia. N Engl J Med. 2014;370:997\u20131007.","journal-title":"N Engl J Med"},{"key":"3689_CR11","doi-asserted-by":"publisher","first-page":"2446","DOI":"10.1182\/blood-2018-05-850461","volume":"132","author":"IW Flinn","year":"2018","unstructured":"Flinn IW, Hillmen P, Montillo M, Nagy Z, Ill\u00e9s \u00c1, Etienne G, et al. The phase 3 DUO trial: duvelisib vs ofatumumab in relapsed and refractory CLL\/SLL. Blood. 2018;132:2446\u201355.","journal-title":"Blood"},{"key":"3689_CR12","doi-asserted-by":"crossref","unstructured":"Wierda WG, Brown J, Abramson JS, Awan F, Bilgrami SF, Bociek G, et al. NCCN Guidelines\u00ae Insights: chronic lymphocytic leukemia\/small lymphocytic lymphoma, version 3.2022. J Natl Compr Canc Netw. 2022;20:622\u201334.","DOI":"10.6004\/jnccn.2022.0031"},{"key":"3689_CR13","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.annonc.2020.09.019","volume":"32","author":"B Eichhorst","year":"2021","unstructured":"Eichhorst B, Robak T, Montserrat E, Ghia P, Niemann CU, Kater AP, et al. Chronic lymphocytic leukaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2021;32:23\u201333.","journal-title":"Ann Oncol"},{"key":"3689_CR14","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1007\/s12185-015-1900-3","volume":"103","author":"K Tobinai","year":"2016","unstructured":"Tobinai K, Ogura M, Ishizawa K, Suzuki T, Munakata W, Uchida T, et al. Safety and tolerability of ibrutinib monotherapy in Japanese patients with relapsed\/refractory B cell malignancies. Int J Hematol. 2016;103:86\u201394.","journal-title":"Int J Hematol"},{"key":"3689_CR15","doi-asserted-by":"publisher","first-page":"2405","DOI":"10.1111\/cas.14886","volume":"112","author":"K Izutsu","year":"2021","unstructured":"Izutsu K, Ando K, Ennishi D, Shibayama H, Suzumiya J, Yamamoto K, et al. Safety and antitumor activity of acalabrutinib for relapsed\/refractory B-cell malignancies: A Japanese phase I study. Cancer Sci. 2021;112:2405\u201315.","journal-title":"Cancer Sci"},{"key":"3689_CR16","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1007\/s12185-020-03024-3","volume":"113","author":"K Izutsu","year":"2021","unstructured":"Izutsu K, Yamamoto K, Kato K, Ishikawa T, Fukuhara N, Terui Y, et al. Phase 1\/2 study of venetoclax, a BCL-2 inhibitor, in Japanese patients with relapsed or refractory chronic lymphocytic leukemia and small lymphocytic lymphoma. Int J Hematol. 2021;113:370\u201380.","journal-title":"Int J Hematol"},{"key":"3689_CR17","doi-asserted-by":"publisher","first-page":"2078","DOI":"10.1182\/blood-2010-02-271171","volume":"116","author":"SE Herman","year":"2010","unstructured":"Herman SE, Gordon AL, Wagner AJ, Heerema NA, Zhao W, Flynn JM, et al. Phosphatidylinositol 3-kinase-\u03b4 inhibitor CAL-101 shows promising preclinical activity in chronic lymphocytic leukemia by antagonizing intrinsic and extrinsic cellular survival signals. Blood. 2010;116:2078\u201388.","journal-title":"Blood"},{"key":"3689_CR18","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1038\/nature20554","volume":"539","author":"O De Henau","year":"2016","unstructured":"De Henau O, Rausch M, Winkler D, Campesato LF, Liu C, Cymerman DH, et al. Overcoming resistance to checkpoint blockade therapy by targeting PI3K\u03b3 in myeloid cells. Nature. 2016;539:443\u20137.","journal-title":"Nature"},{"key":"3689_CR19","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1038\/nature19834","volume":"539","author":"MM Kaneda","year":"2016","unstructured":"Kaneda MM, Messer KS, Ralainirina N, Li H, Leem CJ, Gorjestani S, et al. PI3K\u03b3 is a molecular switch that controls immune suppression. Nature. 2016;539:437\u201342.","journal-title":"Nature"},{"issue":"4","key":"3689_CR20","doi-asserted-by":"publisher","first-page":"2236","DOI":"10.4049\/jimmunol.173.4.2236","volume":"173","author":"K Reif","year":"2004","unstructured":"Reif K, Okkenhaug K, Sasaki T, Penninger JM, Vanhaesebroeck B, Cyster JG. Cutting edge: differential roles for phosphoinositide 3-kinases, p110gamma and p110delta, in lymphocyte chemotaxis and homing. J Immunol. 2004;173(4):2236\u201340.","journal-title":"J Immunol"},{"key":"3689_CR21","doi-asserted-by":"crossref","unstructured":"Faia K, White K, Proctor J, Andrade P, Pink M, Rickles R, et al. High throughput in vitro combination sensitivity screen in hematologic malignancies with the phosphoinositide-3 kinase (PI3K)-\u03b4, \u03b3 inhibitor, duvelisib. J Clin Oncol. 2015;33(15_suppl):8559.","DOI":"10.1200\/jco.2015.33.15_suppl.8559"},{"key":"3689_CR22","doi-asserted-by":"publisher","first-page":"504","DOI":"10.1007\/s12185-020-02929-3","volume":"112","author":"K Izutsu","year":"2020","unstructured":"Izutsu K, Kato K, Kiyoi H, Yamamoto G, Shimada K, Akashi K. Phase I study of duvelisib in Japanese patients with relapsed or refractory lymphoma. Int J Hematol. 2020;112:504\u20139.","journal-title":"Int J Hematol"},{"key":"3689_CR23","doi-asserted-by":"publisher","first-page":"5446","DOI":"10.1182\/blood-2007-06-093906","volume":"111","author":"M Hallek","year":"2008","unstructured":"Hallek M, Cheson BD, Catovsky D, Caligaris-Cappio F, Dighiero G, D\u00f6hner H, et al. Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines. Blood. 2008;111:5446\u201356.","journal-title":"Blood"},{"key":"3689_CR24","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1200\/JCO.2006.09.2403","volume":"25","author":"BD Cheson","year":"2007","unstructured":"Cheson BD, Pfistner B, Juweid ME, Gascoyne RD, Specht L, Horning SJ, et al. Revised response criteria for malignant lymphoma. J Clin Oncol. 2007;25:579\u201386.","journal-title":"J Clin Oncol"},{"key":"3689_CR25","doi-asserted-by":"publisher","first-page":"2590","DOI":"10.1182\/blood-2011-11-390989","volume":"119","author":"MF de Rooij","year":"2012","unstructured":"de Rooij MF, Kuil A, Geest CR, Eldering E, Chang BY, Buggy JJ, et al. The clinically active BTK inhibitor PCI-32765 targets B-cell receptor- and chemokine-controlled adhesion and migration in chronic lymphocytic leukemia. Blood. 2012;119:2590\u20134.","journal-title":"Blood"},{"key":"3689_CR26","doi-asserted-by":"crossref","unstructured":"Barrientos J, Flinn IW, Davids MS, Cashen A, Chiorazzi N, Chen SS, et al. Patterns of Duvelisib-Induced Lymphocytosis in Patients With Relapsed\/Refractory Chronic Lymphocytic Leukemia\/Small Lymphocytic Lymphoma, Including Those With High-Risk Factors Treated in the DUO Trial. Poster presented at: Society of Hematologic Oncology; September 11\u201314, 2019; Houston, TX.","DOI":"10.1016\/j.clml.2019.07.208"},{"key":"3689_CR27","unstructured":"COPIKTRA [prescribing information (United States)]. Secura Bio, Inc. Las Vegas, NV. 2021."},{"key":"3689_CR28","doi-asserted-by":"publisher","first-page":"1391","DOI":"10.1200\/JCO.18.01460","volume":"37","author":"JP Sharman","year":"2019","unstructured":"Sharman JP, Coutre SE, Furman RR, Cheson BD, Pagel JM, Hillmen P, et al. Final results of a randomized, phase III study of rituximab with or without idelalisib followed by open-label idelalisib in patients with relapsed chronic lymphocytic leukemia. J Clin Oncol. 2019;37:1391\u2013402.","journal-title":"J Clin Oncol"},{"key":"3689_CR29","doi-asserted-by":"publisher","first-page":"1427","DOI":"10.1038\/s41375-018-0318-3","volume":"33","author":"BS Hanna","year":"2019","unstructured":"Hanna BS, Roessner PM, Scheffold A, Jebaraj BMC, Demerdash Y, \u00d6zt\u00fcrk S, et al. PI3K\u03b4 inhibition modulates regulatory and effector T-cell differentiation and function in chronic lymphocytic leukemia. Leukemia. 2019;33:1427\u201338.","journal-title":"Leukemia"},{"key":"3689_CR30","doi-asserted-by":"publisher","first-page":"1105","DOI":"10.1080\/14740338.2020.1802424","volume":"19","author":"S Makita","year":"2020","unstructured":"Makita S, Hosoba R, Tobinai K. Safety considerations with targeted therapy drugs for B-cell non-Hodgkin lymphoma. Expert Opin Drug Saf. 2020;19:1105\u201320.","journal-title":"Expert Opin Drug Saf"},{"issue":"6","key":"3689_CR31","doi-asserted-by":"publisher","first-page":"911","DOI":"10.1007\/s12185-022-03450-5","volume":"116","author":"H Goto","year":"2022","unstructured":"Goto H, Izutsu K, Ennishi D, Mishima Y, Makita S, Kato K, et al. Zandelisib (ME-401) in Japanese patients with relapsed or refractory indolent non-Hodgkin\u2019s lymphoma: an open-label, multicenter, dose-escalation phase 1 study. Int J Hematol. 2022;116(6):911\u201321.","journal-title":"Int J Hematol"},{"key":"3689_CR32","doi-asserted-by":"crossref","unstructured":"Vorobyev V, Yoon DH, Ka\u017amierczak M, Grosicki S, Tarella C, Genua A, et al. TEMPO: A phase 2, randomized, open-label, 2-arm study comparing two intermittent dosing schedules of duvelisib in subjects with indolent non-Hodgkin lymphoma (INHL). HemaSphere, 2022;6:(S3):1950\u20131.","DOI":"10.1097\/01.HS9.0000847360.49139.75"},{"key":"3689_CR33","doi-asserted-by":"publisher","first-page":"888","DOI":"10.1182\/blood-2017-08-802470","volume":"131","author":"SM Horwitz","year":"2018","unstructured":"Horwitz SM, Koch R, Porcu P, Oki Y, Moskowitz A, Perez M, et al. Activity of the PI3K-\u03b4, \u03b3 inhibitor duvelisib in a phase 1 trial and preclinical models of T-cell lymphoma. Blood. 2018;131:888\u201398.","journal-title":"Blood"},{"key":"3689_CR34","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1080\/14712598.2019.1572746","volume":"19","author":"Y Ito","year":"2019","unstructured":"Ito Y, Makita S, Tobinai K. Development of new agents for peripheral T-cell lymphoma. Expert Opin Biol Ther. 2019;19:197\u2013209.","journal-title":"Expert Opin Biol Ther"}],"container-title":["International Journal of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12185-023-03689-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12185-023-03689-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12185-023-03689-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,1,31]],"date-time":"2024-01-31T14:33:47Z","timestamp":1706711627000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12185-023-03689-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12,27]]},"references-count":34,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2024,2]]}},"alternative-id":["3689"],"URL":"https:\/\/doi.org\/10.1007\/s12185-023-03689-6","relation":{},"ISSN":["0925-5710","1865-3774"],"issn-type":[{"value":"0925-5710","type":"print"},{"value":"1865-3774","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,12,27]]},"assertion":[{"value":"16 February 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 November 2023","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 December 2023","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 December 2023","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}